FATE
Fate Therapeutics, Inc.
Biotechnology · Healthcare · United States
2.08
close · 2026-10-30
value
7
cheaper than peers7
quality
15
stronger fundamentals15
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 1.58× | 79 |
| price to sales | 38.40× | 27 |
| earnings yield, 2 years ago | -78.8% | 21 |
| cash flow yield, latest year | -45.0% | 20 |
| earnings yield, latest year | -55.3% | 19 |
| cash flow yield, 1 year ago | -49.6% | 17 |
| cash flow yield, 2 years ago | -55.5% | 17 |
| earnings yield, 1 year ago | -78.8% | 17 |
| earnings yield, 3 years ago | -139.9% | 12 |
| cash flow yield, 3 years ago | -113.9% | 11 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -60.8% | 41 |
| revenue growth | 9.2% | 40 |
| debt to equity | 49.3% | 32 |
| operating margin | -1495.4% | 16 |
4 of 4 measures available
Facts
| market cap | $249M |
| free cash flow | -$41.6M |
| employees | 161 |
| first trade | 2013-10-01 |
| next earnings | 2026-08-13 |
| fundamentals updated | 2026-08-18 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.15 | -1.64 | -1.64 | -2.91 |
| free cash flow | -$112.0M | -$123.6M | -$138.4M | -$283.8M |
| net income | -$136.3M | -$186.3M | -$160.9M | -$281.7M |
| revenue | $6.6M | $13.6M | $63.5M | $96.3M |
| unusual items | $244,000 | -$13.9M | $2.5M | $20.3M |